Greek pharma trade group SFEE warns on pharma budgets

22 September 2014
medical_legal_law_big

The members of Greece’s pharma trade group SFEE have called on the government to urgently reset the amount of pharmaceutical expenditure at the minimum permissible limit of 2.3 billion euros ($2.95 billion) for the pharmaceutical budget and 700 million euros for the pharmaceutical costs of public hospitals, warning that the consequences of poor pharmaceutical care provision for Greeks will be enormous and unfortunately unpredictable. Public health at huge risk, with entrepreneurship in an impasse.

They say that the State unloads on the pharmaceutical industry the burden of vaccination costs and coverage of the uninsured. The State decides without any consultation with the industry and legislates against entrepreneurship. There is a total disregard for any notion of justice, lack of transparency and will to reach an understanding, and non-compliance with legislation.

In addition, they call on the Ministry of Health to proceed immediately to the following:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical